Opus Genetics, Inc. (IRD)vsNovartis AG ADR (NVS)
IRD
Opus Genetics, Inc.
$4.99
-6.90%
HEALTHCARE · Cap: $356.30M
NVS
Novartis AG ADR
$146.03
+0.44%
HEALTHCARE · Cap: $277.42B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 398449% more annual revenue ($56.58B vs $14.20M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
IRD
Avoid17
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IRD.
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$146.03
$35.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : IRD
The strongest argument for IRD centers on Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : IRD
The primary concerns for IRD are EPS Growth, Market Cap, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
IRD profiles as a value stock while NVS is a declining play — different risk/reward profiles.
IRD carries more volatility with a beta of 0.63 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 17/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Opus Genetics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Opus Genetics, Inc. (IRD) is a leading biotechnology firm focused on developing innovative gene therapies for rare retinal diseases that threaten vision. Utilizing advanced research and proprietary gene-editing technologies, Opus aims to address critical unmet medical needs with transformative solutions designed to restore sight. The company's commitment to ocular health, coupled with its robust pipeline supported by ongoing clinical trials and strategic collaborations, positions Opus as a key player in the biotech sector. This innovative approach not only enhances patient outcomes but also presents significant value creation opportunities for investors interested in healthcare advancements.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?